Clinical Trial Update: Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting

View source ↗

Summary

A completed real-world observational study evaluating the safety and adverse events of olaparib in Chinese patients with ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Using NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE | Status: COMPLETED